231 results about "Protopanaxadiol" patented technology

The invention discloses a recombinant microorganism for preparing dharma diene and protopanoxadiol and a construction method of the recombinant microorganism. The construction method of the recombinant bacteria comprises a step of adding dharma diene synthase, protopanoxadiol synthase and nicotinamide adenine dinucleotide phosphate - cytochrome P450 reductase encoding gene into saccharomyces cerevisiae to obtain recombinant bacteria I. According to the recombinant microorganism for preparing the dharma diene and the protopanoxadiol and the construction method of the recombinant microorganism, by means of homologous recombination, the dharma diene synthase, the protopanoxadiol synthase and the nicotinamide adenine dinucleotide phosphate - the cytochrome P450 reductase encoding gene are all added into the saccharomyces cerevisiae to obtain the initial recombinant bacteria, and the effect that the initial recombinant bacteria can produce trace amount of the dharma diene and trace amount of the protopanoxadiol is discovered; tHMG1 activity of the initial recombinant bacteria is further improved, and therefore intermediate recombinant bacteria are obtained, and by means of the intermediate recombinant bacteria, the yield of the dharma diene and the yield of the protopanoxadiol are significantly increased; the activity of one or two or three of ERG1, ERG9 and ERG20 are improved on the basis of the intermediate recombinant bacteria, and the effect that the recombinant bacteria which can be used to increase the yield of the dharma diene and the yield of the protopanoxadiol are constructed is also discovered. By means of the recombinant microorganism for preparing the dharma diene and the protopanoxadiol and the construction method of the recombinant microorganism, the foundation is laid for artificially synthesizing the dammar diene and the protopanoxadiol.

The invention pertains to the technical field of biology and medicine, and relates to a bacterial strain of streptomyces fradiae NTGA-334 with a preseravation no. of CGMCC No.2074, and a process for using the bacterial strain to ferment and transform Compound K in glycol group in various notoginsenosides so as to prepare 20-O-beta-D-glucopyranoside-20 (S)-protopanaxadiol. The culture media are Gause's no.1, ISP2, corroding acid (HSG culture medium) and asparagine culture medium. During the fermentation, the dosing proportions of various notoginsenosides are 0.1-10% (w / v), fermenting temperature is 18-50 DEG C, dynamically adjusted pH value of 0.1-35%(w / v) aqueous ammonia is 0.1-30% (w / v). The invention transforms and ferments in a scaled way various notoginsenosides, prepares Compound K, provides a streptomycete stain that is of steady condition, simple nutrition requirement and good growth, and provides a process for fermenting and separating by a simple and easy fully automatic fermenting tank. Using this bacterial strain and process to produce Compound K, the production cost is low, the foreign matter is less, and the yield rate is high.

The invention relates to the process for preparing protopanoxadiol and protopanaxatriol by using general saponin extract from panax ginseng plant leaves and gynostemma pentaphylla extractive as raw material for alkaline hydrolysis reaction in organic solvent through column chromatography and purification.

The invention relates to medical application of protopanaxa-triol (PPT), protopanaxadiol (PPD) and mixtures of the PPT and the PPD in any proportion in nervous system diseases, which are preferably used for treating and / or preventing epilepsy, cerebral ischemic diseases, memory disorder and parkinsonism syndrome.

The invention relates to application of a 20(S)-ginsenoside Rh2, namely 20(S)-protopanoxadiol-3-O-beta-D-glucopyranoside compound in the field of pharmacy. The compound can confront the swimming fatigue action of tumor-bearing animals and enhance the oxygen deficit resistance and immunologic function of the tumor-bearing animals. The safety experiment shows that the compound has high safety, does not influence the central nervous system, cardiovascular system and respiratory system of animals, and has no mutagenesis function. The clinical research shows that the compound can effectively reduce the brief fatigue index BFI score of a tumor patient, improve the functional evaluation FACTIT-F score of chronic disease treatment, improve the KPS score, and simultaneously relieve Chinese medicine symptoms so as to improve the fatigue degree of the tumor patient. The compound has high safety and good anti-fatigue function under test dose, and can be used for the treatment of fatigue, in particular cancer related fatigue.

The present invention provides an anticancer auxiliary medicine using 20(S)-protopanaxadiol as effective component and its application. Said medicine possesses the action of raising therapeutic effect of anticancer medicine, reducing toxicity of anticancer medicine, preventing and curing leukopenia due to radiotherapy and chemotherapy and raising immunity of human body, and can be used for auxiliary therapy of carcinoma.

The invention discloses recombinant saccharomyces cerevisiae for producing dammarenediol and protopanoxadiol using xylose and a construction method. The construction method comprises the steps of replacing a promoter of a saccharomyces cerevisiae xylulokinase gene XKS1 with a promoter PFBA1 by virtue of a homologous recombination method, introducing xylose reductase XYL1 and a xylitol dehydrogenase XYL2 expression cassette, increasing the activities of transketolase TKL1 and transaldolase TAL1 so as to obtain recombinant bacteria 1, introducing a farnesyl-diphosphate farnesyltransferase gene ERG9, a squalene monooxygenase gene ERG1 and a dammarenediol synthase gene DS into the recombinant bacteria 1 so as to obtain recombinant bacteria 2, and introducing a nicotinamide adenine dinucleotide-hydroxymethylglutaryl coenzyme A reductase gene NADH-HMGr, farnesyl diphosphatesynthase ERG20 and a protopanoxadiol synthase-cytochrome P450 reductase fusion protein gene PPDS-ATR1 into the recombinant bacteria 2, so as to obtain recombinant bacteria 3. According to the recombinant saccharomyces cerevisiae, dammarenediol and protopanoxadiol can be artificially synthesized by virtue of xylose.

The invention relates to a combination made of 20(R)-ginsenoside taken serving as active constitutent and the application of the combination as medicine or health products. The 20(R)-ginsenoside combination mainly comprises the following weight percentage compositions of the components: 30 percent to 60 percent of 20(R)-ginsenoside Rg3, 10 percent to 40 percent of 20(R)-ginsenoside Rh2 and 10 percent to 30 percent of ginsenoside III, wherein the ginsenoside III is 20(R)-protopanoxadiol-3-O-beta-pyrane xylopyranosyl (1-2) beta-D-pyrane glucosyl (1-2) beta -D-pyrane glucoside. The invention relates to application of the drug combination in preparing anticancer aided drug for preventing and curing leucocyte reduction caused by radiotherapy and chemotherapy and in medicine or health products improving human body immunity.

The invention relates to a 20S-protopanaxadiol beta-cyclodextrin inclusion compound which can be used for preparing medicines and foods for resisting tumors, protecting the liver, reducing blood fat, reducing blood sugar, promoting gastric secretion, promoting appetite, improving digestion functions, enhancing immunity, resisting oxidization and resisting senescence. The invention also relates toa preparation process as well as composition of the inclusion compound.

The invention discloses a recombinant saccharymyces cerevisiae for producing ginsengenins as well as a construction method and an application of the same. The recombinant saccharymyces cerevisiae capable of producing three ginsengenins of oleanolic acid, protopanoxadiol and protopanaxatriol simultaneously is Saccharymyces cerevisiae GY-1, with a collection number of CGMCC No. 7725 in the China General Microbiological Culture Collection Centre. The saccharymyces cerevisiae GY-1 is capable of producing three ginsengenins of oleanolic acid, protopanoxadiol and protopanaxatriol simultaneously, wherein the yields achieve 21.4 mg / L in fermentation broth, 17.2 mg / L in fermentation broth and 15.9 mg / L in fermentation broth respectively, the proportions of which in the total ginsengenin content are 39.3%, 31.5% and 29.2% respectively.

The invention discloses a production method of rare ginsenoside Rh2 and belongs to the field of enzymatic synthesis of ginsenoside. The production method includes that protopanoxadiol is used as a substrate, glycosyltransferase YjiC or YojK screened from bacillus subtilis is used as a catalyst, and the glycosylation of the C3 hydroxyl of the protopanoxadiol is efficiently catalyzed through in-vitro enzyme reaction to generate the ginsenoside Rh2. The production method is cheap in raw materials, high in ginsenoside Rh2 yield, low in production cost and capable of achieving large-scale production of the precious and rare ginsenoside Rh2.

The invention discloses a co-catalytic reaction system for preparing rare ginsenosides. The co-catalytic reaction system comprises glycosyltransferase GT (a); sucrose synthase SUS (b); uridine diphosphate UDP (c); and saccharose (d). Experiments show that in the presence of the saccharose and little UDP, an enzyme combination composed of the glycosyltransferase and the saccharose is capable of replacing an in-vitro reaction system to synthesize UDP sugar, one of expensive materials for the rare ginsenosides, and efficiently and economically converting substrates such as protopanoxadiol or protopanaxatriol into the rare ginsenosides, wherein the UDP is about 1 / 4 of the UDP sugar in price and is 1% of its original dosage; thus, preparation cost of the rare ginsenosides is greatly saved, and large-scale commercial preparation of the ginsenosides is better facilitated.

The invention discloses applications of glycosyltransferase and related materials thereof in the construction of engineering bacteria for producing ginsenoside Rb1 and Rg1. A glycosyltransferase genePn3-32 which can catalyze ginsenoside Rd to generate ginsenoside Rb1 can be successfully identified through a synthetic biological method; and the gene can simultaneously catalyze ginsenoside F1 to generate ginsenoside Rg1 and construct recombinant yeast producing the ginsenoside Rb1 and the ginsenoside Rg1. Through experiments, the constructed recombinant yeast producing the ginsenoside Rb1 and the ginsenoside Rg1 can simultaneously generate the ginsenoside Rb1 and the ginsenoside Rg1. Pn1-31, Pn-3-29, Pn3-31 and Pn3-32 glycosyltransferase genes in medicinal plant radix notoginseng are firstly utilized to continuously catalyze protopanaxadiol and protopanaxatriol to synthetize the ginsenoside Rb1, the ginsenoside Rg1 and corresponding intermediates, so that novel cases can be provided formicrobial strains to produce natural products.

The invention discloses a protopanoxadiol peroxide derivatives as well as a preparation method and an application of the protopanoxadiol peroxide derivatives. The structural formulae of the protopanoxadiol peroxide derivatives disclosed by the invention are shown in formulae I, II and III. In the method, the microbial conversion technology is utilized to modify structure of protopanoxadiol successfully so as to obtain various novel compounds. In-vitro anti-tumor cell test shows that the compounds have better anti-tumor activity, so that the compounds can be used as active components of the anti-tumor drug and have wide application.

This invention relates to a method for preparing protopanaxadiol and protopanaxatriol by co-oxidizing with oxygen and peroxide and alkali-hydrolyzing total notoginsenoside. The method comprises: (1) oxidizing and alkali-hydrolyzing Panax ginseng total saponin extract and Gynostemma pentaphyllum total saponin extract by applying cooperative effect of oxygen and peroxide, and alkali-hydrolyzing using alkoxide in situ formed in alcohol at 80-95 swg..C for 8-24 h, where the Panax ginseng total saponin extract and Gynostemma pentaphyllum total saponin extract / alcohol ratio is 30-150 g / L; (2) purifying by column chromatography to obtain protopanaxadiol and protopanaxatriol. The method adopts cooperative effect of oxygen and peroxide, thus can obtain high-purity protopanaxadiol and protopanaxatriol with high yields at low reaction temperatures and short reaction time. This invention provides a simple, convenient and low-cost method for preparing protopanaxadiol and protopanaxatriol in large amounts, which can satisfy the needs of drugs for treating cardiovascular and cerebrovascular diseases and tumor.

The invention relates to a biosynthesis method of dammarenediol and provides a producing strain of the dammarenediol. A pichia pastoris engineering strain, which can recombine and express a dammarenediol synthetic enzyme with high efficiency, is constructed through a genetic engineering technical means, a precursor for synthesizing protopanaxadiol, namely the dammarenediol is further synthesized, and a foundation is finally laid for biosynthesis and large-scale industrial production of the protopanaxadiol.

The invention discloses a method for converting ginsenoside through plant complex enzyme. The method comprises the following steps that ginseng is ground into powder, subjected to low-temperature sterilization and then cooled to the room temperature; the sterilized ginseng powder is evenly mixed with the plant complex enzyme, moisture is adjusted through a sterile LL liquid culture medium and distilled water, the mixture is fully mixed to be uniform, then sealed and put into a constant-temperature incubator for fermentation, and a ginseng fermentation product is obtained; an 80% methyl alcohol aqueous solution is used for ultrasonic extraction, filtering is carried out, filtrate is subjected to vacuum concentration, and coarse ginsenoside extract is obtained; the coarse ginsenoside extract is dissolved by adding deionized water, then subjected to extraction through a saturate n-butyl alcohol solution and subjected to vacuum concentration, and ginsenoside extract is obtained, wherein the ginsenoside extract contains rare ginsenoside with fewer sugar chains or an antineoplastic active material protopanoxadiol (PPD) without sugar chains. The method is simple in process and convenient to implement, and the product is easy to dry; most importantly, in the solid fermentation process, conversion of ginsenoside is achieved, and the rare ginsenoside or the antineoplastic active material protopanoxadiol (PPD) is obtained.

The invention discloses a gene PgPDR3 (panax ginseng pleiotropic drug resistance) related to promotion of transport and accumulation of ginsenosides, as well as an encoding protein and an application of the gene PgPDR3. A sequence of the PgPDR3 gene related to the transport and the accumulation of the ginsenosides is shown as SEQ ID No. (sequence identification number) 1; and the sequence of the encoding protein of the PgPDR3 gene is shown as SEQ ID No. 2. The research finds that PgPDR3 gene expression has tissue specificity and is closely related to the accumulation of the ginsenosides. The PgPDR3 gene has significant effects of promoting synthesis, the transport and the accumulation of the ginsenosides. Panax ginseng or other plants can be screened or improved through the PgPDR3 gene or derivatives of the PgPDR2 gene to obtain excellent plant varieties with high ginsenoside content. Also, panax ginseng transgenic cells or plants can be adopted to produce ginsenoside monomers such as protopanaxadiol, Rb, Re, Rh2, Rg2 and Rg3.

The present invention relates to a series of dicarboxylic acid ester derivatives of ginsenosides such as succinate and glutarate derivatives of 20-O-β-D-glucopyranosyl-protopanaxadiol (compound K, abbreviated as CK), preparation thereof and pharmaceutical uses thereof. The dicarboxylic acid ester derivatives of ginsenosides of the present invention can be used to form pharmaceutical acceptable salts thereof having a high water solubility or can be directly dissolved in an aqueous solution of metal salt, and retain the pharmaceutical activities of ginsenosides such as tumor growth inhibition and cancer preventive cytotoxicity. The dicarboxylic acid ester derivatives of ginsenosides of the present invention are thus suitable for use in the manufactures of various pharmaceutically and cosmetically acceptable dosage forms of preparations, such as peripheral, oral, and topical dosage forms.

Various glycoside compounds and particularly glycoside compounds which are unstable, easy to oxidize and difficult to dissolve in water and an organic solvent are hydrolyzed under the actions of adsorption, dispersion, curing and settlement of macroporous adsorption resin to generate aglycone or a mixture of the aglycone and secondary glucoside, and the macroporous adsorption resin is secondarily eluted or primarily eluted by using an organic solvent to obtain aglycone, secondary glucoside and a mixture of the aglycone and the secondary glucoside. The invention provides a universal method for preparing the aglycone and the secondary glucoside by using the various glycoside compounds, the method is simple in operation, almost integrated in hydrolysis and separation, high in product purity, good in product yield, free of expensive reagent, capable of realizing repeated utilization of hydrolysate and the macroporous adsorption resin, environment-friendly, easy for realizing industrial production and low in cost and has great advantages as comparison with an enzyme hydrolysis method, a fermentation method and the like. By taking the hydrolysis of the total saponin of panax ginseng as an example, through the hydrolysis of acetic acid and other acids, more prosapogenins Rh2 of panax ginseng and protopanaxadiol aglycones are obtained, but a C17 side chain cyclization product is not obvious.

Provided is a nicotinamide adenine dinucleotide (NADPH)-cytochrome P450 reductase and a use thereof. Also provided is a polynucleotide encoding the NADPH-cytochrome P450 reductase, an expression vector and a host cell which express the NADPH-cytochrome P450 reductase, and a method for producing the protopanoxadiol.

The invention provides a preparation method of ginsenoside CK and relates to a method for preparing 20-O-beta-D-glucopyranosyl-20-protopanoxadiol (ginsenoside CK) by fermenting and converting protopanoxadiol in a full-automatic fermentation tank by means of a bacterial strain. The method comprises the following steps: (1) culture of microorganisms; (2) fermentation and conversion of microorganisms; and (3) chromatographic separation and purification by macroporous resin to finally obtain a compound with the chemical name: 20-O-beta-D-glucopyranosyl-20-protopanoxadiol (ginsenoside CK).

The invention provides a high-performance liquid chromatography (HPLC) method for simultaneously determining 16 ginseng saponin monomers, such as Rg1, Re, Rf, Rb1, Rg2, Rc, Rb2, Rb3, F1, Rd, F2, Rg3, protopanaxatriol, Compound K, Rh2 and protopanaxadiol. The determination range comprises medicinal plants such as ginseng and American ginseng containing more than one saponin monomer, and preparations thereof. Compared with the prior art, the HPLC method has the advantages that the variety of the ginseng saponin monomers simultaneously determined by the method can be up to 16, and the efficiency is improved. Only are acetonitrile and water used as mobile phases, so that the problems that phosphate is large in loss on a chromatographic column, the system is troublesome to clean and the like are solved. The built HPLC method is wide in linearity range, accurate in method, good in reproducibility, fast and convenient, stable and reliable. A theoretical basis is provided for quality control of the medicinal plants, such as ginseng and American ginseng, and the preparations thereof.

Medicinal composition containing ginseng secondary glycosides, its preparation method and application. The present composition contains mainly, as active ingredients, the ginsenoside with protopanoxadiol as aglucone (ginsenoside Rg3) and the ginsenoside with protopanoxatriol as aglucone (ginsenoside Rg2 and ginsenoside Rh1). It is prepared from the ginseng genus of plants through extracting, acid hydrolyzing and using macroreticular resin to separate, purify and concentrate. It is useful in the manufacture of medicaments for treating CHD, angina pectoris, myocardial ischemia, hemorrhagic shock, heart failure, and arrhythmia.

The present invention relates to Rhodanobacter ginsenosidimutans KCTC22231T-derived ginsenoside glycosidase and use thereof, and this protein has an activity of converting PPD (protopanaxadiol)-type saponins into in vivo absorbable, highly active deglycosylated saponins by selective hydrolysis of a bond at a particular position of ginsenoside. More particularly, the present invention relates to an amino acid sequence constituting the protein, a nucleic acid sequence encoding the protein, a recombinant vector comprising the nucleic acid sequence, a transformant transformed with the vector, a method for preparing Rhodanobacter ginsenosidimutans KCTC22231T-derived ginsenoside glycosidase by culturing the transformant, a method for converting PPD (protopanaxadiol)-type major ginsenoside into a rare ginsenoside that is absorbable in vivo using the protein, and a composition for converting PPD-type saponins into in vivo absorbable saponins, comprising the protein as an active ingredient.

The invention discloses a composition for resisting ageing and improving male energy. The composition is prepared from a raw material and an auxiliary material; the raw material is prepared from the following components in parts by weight: 1-15 parts of nicotinamide mononucleotide, 1-10 parts of protopanoxadiol, 1-9 parts of icarisid I, 2-8 parts of baohuoside I, 3-7 parts of dehydroepiandrosterone and 2-10 parts of ursodesoxycholic acid. The composition is reasonable in composing prescription and proper in compatibility; in the composition, the four of the nicotinamide mononucleotide (NMN), the icarisid I, the baohuoside I and protopanoxadiol are used as monarch drugs together, the composition is capable of comprehensively regulating gonad axis and invigorating kidney-yang and liver, candelay ageing period of the gonad axis and improve the sexual function after being taken for a long time; through intercoordination and synergistic effect of various components, the composition is comprehensive in nutrition, has very good palatability, is particularly suitable for males to take and thus relieving the symptoms of male ageing syndrome and improving the male energy. The invention alsoprovides a preparation containing the composition and a preparation method of the preparation. The preparation method is simple, is moderate in condition and is suitable for industrial batch production.

Provided are a novel UDP-glycosyltransferase (uridine diphosphate glycosyltransferase) protein from Dolwoe (Gynostemma pentaphyllum) having glycosyltransfer activity for glucose linked by a glycosidic bond at the C-20 position of PPD (protopanaxadiol)-type or PPT (protopanaxatriol)-type ginsenoside, and use thereof.